Alexion is focused on providing innovative treatments to patients with life-threatening rare diseases for which there are few, if any, effective treatment options. Alexion established operations in Sydney in 2008 to serve patients in the Australia and Asia region. We aim to work in partnership with all stakeholders including healthcare providers, patient advocacy organisations and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.
In Australia, SOLIRIS® (eculizumab, rmc) is registered for the treatment of atypical haemolytic uraemic syndrome (aHUS) and paroxysmal nocturnal haemoglobinuria (PNH), and for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive, three devastating, ultra-rare, complement-mediated diseases. SOLIRIS has been funded via the Pharmaceutical Benefits Scheme Section 100 Highly Specialised Drugs Program for aHUS since December 2014 and via the Life Saving Drugs Program for PNH since January 2011. For the treatment of NMOSD, SOLIRIS is not listed on the PBS. Product Information for SOLIRIS can be accessed here.
ULTOMIRIS® (ravulizumab rch) is a novel treatment option registered in Australia for the treatment of PNH. ULTOMIRIS is not listed on the PBS. Product information can be accessed here.
Alexion’s metabolic portfolio includes two highly innovative enzyme replacement therapies which are both registered in Australia: STRENSIQ® (asfotase alfa rch) for the treatment of paediatric-onset hypophosphatasia (HPP) and KANUMA® (sebelipase alfa rce) for the treatment of lysosomal acid lipase deficiency (LAL-D). Both HPP and LAL-D are severe, ultra-rare metabolic diseases. Alexion is committed to seeking government reimbursement for both products to serve patients suffering from these diseases. Product Information for STRENSIQ can be accessed here and Product information for KANUMA can be accessed here.
Alexion shares key goals with patient organisations worldwide, including increasing the understanding of rare diseases, improving patient care, and enhancing patient access to innovative therapies. Local patient organisations in Australia include:
Working at Alexion is an experience like no other. With a focus on devastating and rare diseases, each endeavor is urgent and every day counts. Groundbreaking innovation, life-saving therapies, all driven by a team with a shared sense of purpose and dedication — that’s Alexion.
Join us to achieve the impossible and do what’s never been done before. Browse job openings in Australia here or contact:
Executive Assistant & HR Operations - Employee Experience